OOIR: Observatory of International Research

Papers

(The median citation count of Seminars in Hematology is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Iron metabolism in infections: Focus on COVID-19	56
Toward a pathophysiology inspired treatment of VEXAS syndrome	45
Aplastic anemia: Pathophysiology	39
Epidemiology of VITT	36
Platelet-activating anti-PF4 disorders: An overview	34
Treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT)	33
Characteristic bone marrow findings in patients with UBA1 somatic mutations and VEXAS syndrome	33
Thrombotic manifestations of VEXAS syndrome	33
Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT)	30
Mechanisms of cellular iron sensing, regulation of erythropoiesis and mitochondrial iron utilization	29
Clonal hematopoiesis and VEXAS syndrome: survival of the fittest clones?	26
Genetics of somatic auto-inflammatory disorders	25
VEXAS within the spectrum of rheumatologic disease	23
Shaping the bone through iron and iron-related proteins	19
VEXAS syndrome: An inflammatory and hematologic disease	17
20 years of Hepcidin: How far we have come	17
Laboratory testing for VITT antibodies	13
Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria	12
Epidemiology and etiology of diffuse large B-cell lymphoma	11
Longitudinal Aspects of VITT	11
Applications of virus-specific T cell therapies post-BMT	11
Immunosuppressive therapy in severe aplastic anemia	10
TET-dioxygenase deficiency in oncogenesis and its targeting for tumor-selective therapeutics	10
Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients	10
DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multipl	9

Hemolytic paroxysmal nocturnal hemoglobinuria: 20 years of medical progress	9
Looking beyond VEXAS: Coexistence of undifferentiated systemic autoinflammatory disease and myelodysplastic syndrome	9
Clonality in immune aplastic anemia: Mechanisms of immune escape or malignant transformation	9
The epidemiology of Waldenström macroglobulinemia	8
The role of viruses in HIV-associated lymphomas	8
Place of care manufacturing of chimeric antigen receptor cells: Opportunities and challenges	8
The spectrum of somatic mutations in large granular lymphocyte leukemia, rheumatoid arthritis, and Felty's syndrome	7
SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies	7
Extranodal natural killer/T-cell lymphoma: An overview on pathology and clinical management	7
A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies	7
The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia	7
Diagnosis and management of adult T-cell leukemia/lymphoma	7
Advances in understanding the crosstalk between mother and fetus on iron utilization	6
Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia	6
Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin	6
Somatic compensation of inherited bone marrow failure	6
Transforming CLL management with immunotherapy: Investigating the potential of CAR T-cells and bispecific antibodies	5
Clinical picture of VITT	5
Somatic mutations in VEXAS Syndrome and Erdheim-Chester disease: Inflammatory myeloid diseases	5
Palliative care needs of patients with hematologic malignancies and family caregivers and challenges of palliative care provision in Asia: A review of evidence	5
Epigenetic activities in erythroid cell gene regulation	5
Hepatitis C virus-associated B-cell lymphomas: The importance of the new direct antiviral agent therapy	5
Somatic mutations and clonal expansions in paroxysmal nocturnal hemoglobinuria	5
Epigenetic modifier directed therapeutics to unleash healthy genes in unhealthy cells	5
Iron and erythropoiesis: A mutual alliance	5
The natural killer cell immunotherapy platform: An overview of the landscape of clinical trials in liquid and solid tumors	5
Infectious complications of chimeric antigen receptor (CAR) T-cell therapies	4
Clinical applications of circulating tumor DNA in central nervous system lymphoma	4
Somatic mutations in acquired pure red cell aplasia	4
Management of Angioimmunoblastic T-Cell Lymphoma (AITL) and other T Follicular Helper Cell lymphomas (TFH PTCL)	4
Gene editing for sickle cell disease and transfusion dependent thalassemias- A cure within reach	4
Aplastic anemia: Quo vadis?	4
Second-line treatment of diffuse large B‐cell lymphoma: Evolution of options	4
Clonal dynamics of hematopoietic stem cell compartment in aplastic anemia	4
Current challenges and new approaches to implementing optimal management of sickle cell disease in sub-Saharan Africa	4
Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients	4
Vaccine-induced immune thrombotic thrombocytopenia (VITT)	4
Clinical manifestations of clonal hematopoiesis: What has SF3B1-mutant MDS taught us?	4
Novel therapies targeting cutaneous T cell lymphomas and their microenvironment	4
Cell senescence and malignant transformation in the inherited bone marrow failure syndromes: Overlapping pathophysiology with therapeutic implications	4
Molecularly targeted therapies for relapsed and refractory peripheral T-cell lymphomas	3
miRNA Biology in Chronic Lymphocytic Leukemia	3
Prognosis and risk stratification of peripheral T-cell lymphomas	3
Clonal hematopoiesis and autoimmunity	3
Challenges and opportunities of CAR T-cell therapies for CLL	3
Mendelian inheritance of anemia due to disturbed iron homeostasis	3
Primary and secondary central nervous system mature T- and NK-cell lymphomas	3
The psychiatric and psychological sequelae of vaccine-induced immune thrombotic thrombocytopenia (VITT)	3
The biology of classical Hodgkin lymphoma	3
Clonal hematopoiesis in children with predisposing conditions	3

Immune-driven clonal cell selection at the intersection among cancer, infections, autoimmunity and senescence	3
Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management	3
The case for prioritizing malignant hematology services in low- and middle-income countries	2
Highlights of the 11th International Workshop on Waldenstrom's Macroglobulinemia: What we learned, and how it will impact scientific discovery and patient care	2
Biological heterogeneity in diffuse large B-cell lymphoma	2
Inequalities in access to treatment in Argentina: Differences in management of CLL and multiple myeloma?	2
The future of lymphoma diagnosis, prognosis, and treatment monitoring in countries with limited access to pathology services	2
Germline predisposition for clonal hematopoiesis	2
The crossroads of cancer therapies and clonal hematopoiesis	2
Role of the tumor microenvironment in CLL pathogenesis	2
Epigenetic regulation of hemoglobin switching in non-human primates	2
Access to essential therapy for sickle cell disease in Africa: Experience from a national program in Ghana	2
DLBCL arising from indolent lymphomas: How are they different?	2
Contemporary radiation therapy use in Hodgkin lymphoma	1
Lessons learned from the Eµ-TCL1 mouse model of CLL	1
The role of autologous stem-cell transplantation in classical Hodgkin lymphoma in the modern era	1
How to set up a clinical research center in Brazil, as an example of a middle-income country	1
The role of response adapted therapy in the era of novel agents	1
Effective sequencing of chimeric antigen receptor T-cell therapy in the treatment of LBCL in 2023	1
Molecular biomarkers in classic Hodgkin lymphoma	1
Setting up a network of comprehensive care for patients with chronic myeloid leukemia: Lessons learned from Tanzania	1
Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related Amyloidosis	1
The future of aplastic anemia treatment in Brazil: Lessons learned for global hematology	1
Vaccinations in patients with chronic lymphocytic leukemia	1
The pediatric approach to Hodgkin lymphoma	1
Antibody and immunotherapy in diffuse large B-cell lymphoma	1
Metabolic reprogramming in the CLL TME; potential for new therapeutic targets	1
CD19 CAR-T cell therapy for relapsed or refractory diffuse large B cell lymphoma: Why does it fail?	1
Clonal hematopoiesis in the setting of hematopoietic cell transplantation	1
Targeting the B cell receptor signaling pathway in chronic lymphocytic leukemia	1
Measurable residual disease after CAR T-cell therapy	1
Clinical applications of circulating tumor DNA in indolent B-cell lymphomas	1
Prognostication in chronic lymphocytic leukemia	1
Debate: Should the loss of disability adjusted life years (DALY) define the focus of Global Hematology?	1
The molecular map of CLL and Richter's syndrome	1
A tower of babel of acronyms? The shadowlands of MGUS/MBL/CHIP/TCUS	1
Epigenetic modifiers in normal and aberrent erythropoeisis	1
Mouse models of CLL: In vivo modeling of disease initiation, progression, and transformation	1
Looking to achieve cure the first time around for DLBCL patients who are older and/or with co-morbidities	1
Forging international collaboration and alliances to establish the largest transplant center in the north of Vietnam	1
Therapeutic targeting of apoptosis in chronic lymphocytic leukemia	1
Integration of PET in DLBCL	1
The complexities of T-cell dysfunction in chronic lymphocytic leukemia	1
Evidence-based management of primary and secondary CNS lymphoma	1